Relapse rates during follow-up
REGRESSION, REMISSION
A total of 14 patients (14.6%) relapsed during follow-up, including 6 (11.8%), 4 (16.7%), and 4 (19%) from GDR, MT1, and MT2 groups, respectively. Illustrated by the Kaplan-Meier survival curve and examined by Cox regression, Breslow method for ties, there is no significantly different risk of relapse between groups (LR χKaplan-Meier survival estimates of proportions of patients who remained in remission during follow-up. The long dash-dot line represents the guided dose reduction group (GDR), the dashed line represents the Maintenance Group 1 (MT1), and the solid line represents the naturalistic observational comparison group (MT2).In this cohort, no demographic or clinical variables were significantly related to the risk of relapse except baseline PANSS scores; as adjusted for gender and baseline CPZE, higher baseline PANSS scores were associated with increased risk of relapse (HR 1.06, 95% CI 1.01~1.11, 